Literature DB >> 7071811

Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase.

M R Buchanan, J A Rischke, J Hirsh.   

Abstract

Aspirin inhibits platelet function and prevents thrombosis in some clinical situations. This antithrombotic effect is attributed to the irreversible inhibition of platelet thromboxane A2 synthesis, an effect which is achieved by a low dose of aspirin. There is some evidence that higher doses of aspirin may have additional antithrombotic effects. To test this possibility, we measured the effect of high and low dose aspirin on hemostasis in vivo and platelet function ex vivo in the rabbit. Both carotid arteries were isolated. One was replaced with a 2 cm piece of polyethylene tubing and the other was left intact. The prosthetic and intact vessels were then punctured with a needle and the time take for bleeding from each to cease was measured. Aspirin (3 and 100 mg/kg given 1 or 20 hours before hand) had no effect on the bleeding from the intact vessel, but prolonged the bleeding time in the prosthetic vessel in a dose-related manner. Washed platelets obtained from the 100 mg/kg-treated rabbits were less responsive to collagen and thrombin than platelets obtained from the 3 mg/kg-treated rabbits which in turn, were less responsive than control platelets. This additional effect of aspirin on platelet function was not due to the further inhibition of platelet thromboxane A2 release nor to further inhibition of the platelet release phenomenon. It is suggested that the enhanced effect of high dose aspirin on haemostasis from the arterial prosthesis is related to the second platelet inhibiting effect of aspirin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7071811     DOI: 10.1016/0049-3848(82)90127-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  12 in total

Review 1.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 2.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Plasma drug and antiplatelet profiles of the original acetylsalicylic acid preparations used in the AMIS, PARIS and German-Austrian trials for secondary prevention of myocardial infarction.

Authors:  R Simrock; K Rehders; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Aspirin and thrombolytic therapy for acute myocardial infarction. Should the combination now be a routine therapy?

Authors:  T L Schreiber
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

5.  Specific correction of impaired acid hydrolase secretion in storage pool-deficient platelets by adenosine diphosphate.

Authors:  B Lages; C A Dangelmaier; H Holmsen; H J Weiss
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

Review 6.  Unstable angina: 1985 update.

Authors:  J A Cairns
Journal:  CMAJ       Date:  1986-04-01       Impact factor: 8.262

7.  Biological basis and clinical implications of acetylsalicylic acid resistance.

Authors:  Michael R Buchanan
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

Review 8.  Aspirin in cardiovascular disease.

Authors:  I A Reilly; G A FitzGerald
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

Review 9.  Unstable angina: current concepts of medical management.

Authors:  C W Hamm; W Bleifeld
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

10.  Plasma salicylate levels and platelet function after acute and chronic administration of slow-release acetylsalicylic acid (Monobeltin).

Authors:  K Rehders; R Simrock; H Spahn; E Mutschler; H K Breddin
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.